Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc has successfully increased its market share in the cash-pay aesthetic market, driven by a strategic go-to-market approach and the high quality of its product, Jeuveau, which achieves reliable results. The company's fourth quarter performance demonstrated resilience, with revenues expected between $88.6 million and $90.6 million, reflecting a year-over-year growth of 12-15%. Furthermore, management forecasts significant revenue growth for 2026 of $327 million to $337 million, equating to a compound annual growth rate of 15-19% through 2028, along with an expected launch of the "Sculpt" filler in 2027 to further enhance growth potential.

Evolus Inc has revised its long-term financial outlook downward, projecting total net revenue between $450 million and $500 million for 2028, a significant reduction from the prior guidance of $700 million. This adjustment reflects a broader trend of deceleration in the aesthetic market, compounded by various risks such as a challenging consumer spending environment, persistent competition, and higher operating expenses. Additionally, the deterioration of growth expectations has raised concerns among investors regarding the sustainability of Evolus's performance in an increasingly competitive and uncertain market landscape.